Annovis Bio Inc (ANVS)

Apr 26, 2026

Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN

Apr 26, 2026

Apr 24, 2026

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging - TMX Newsfile

Apr 24, 2026

Apr 24, 2026

Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference - TMX Newsfile

Apr 24, 2026

Apr 23, 2026

Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS) - MarketBeat

Apr 23, 2026

Apr 14, 2026

Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo

Apr 14, 2026

Apr 13, 2026

Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -

Apr 13, 2026

Apr 13, 2026

Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com Australia

Apr 10, 2026

Apr 10, 2026

Annovis Bio highlights buntanetap development in published article - MSN

Apr 10, 2026

Apr 10, 2026

Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter

Apr 10, 2026

Apr 10, 2026

Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com

Apr 10, 2026

Apr 10, 2026

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - ChartMill

Apr 10, 2026

Apr 10, 2026

Annovis Bio Announces $10 Million Underwritten Offering to Advance Alzheimer’s and Parkinson’s Drug Development - Minichart

Apr 10, 2026

Apr 10, 2026

Annovis Bio Prices Registered Direct Offering to Fund Trials - TipRanks

Apr 10, 2026

Apr 10, 2026

Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView

Apr 10, 2026

Apr 10, 2026

Weekly Trades: Will Annovis Bio Inc. benefit from rising consumer demand2026 Market Trends & Safe Capital Preservation Plans - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

Quarterly Risk: Will Annovis Bio Inc stock hit new highs in YEAR2026 Growth vs Value & Weekly Breakout Watchlists - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Annovis Bio prices $10M stock offering at $1.90 per share - Investing.com Australia

Apr 09, 2026

Apr 09, 2026

Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan

Apr 09, 2026

Apr 09, 2026

Annovis Bio (ANVS) raises ~$10M via 5.26M-share registered direct offering - Stock Titan

Apr 09, 2026

Apr 09, 2026

Form 424B5 Annovis Bio, Inc. - StreetInsider

Apr 09, 2026

Apr 09, 2026

Annovis Bio stock tumbles 26% on dilutive equity offering By Investing.com - Investing.com India

Apr 09, 2026

Apr 09, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Apr 09, 2026

Apr 09, 2026

Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com

Apr 09, 2026

Apr 09, 2026

Anovis Bio Inc stock: $10M raise amid Phase 3 push – what it means for you - AD HOC NEWS

Apr 09, 2026

Apr 09, 2026

Annovis Bio prices $10M stock offering at $1.90 per share By Investing.com - Investing.com South Africa

Apr 09, 2026

Apr 09, 2026

Annovis announces $10 million underwritten offering of common stock and accompanying warrants - marketscreener.com

Apr 09, 2026

Apr 09, 2026

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants - The Manila Times

Apr 09, 2026

Apr 08, 2026

Annovis Secures U.S. Patent for Buntanetap Neurological Use - MyChesCo

Apr 08, 2026

Apr 08, 2026

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - WFXG

Apr 08, 2026

Apr 08, 2026

Annovis Bio Highlights Buntanetap Development in Published Article - MyChesCo

Apr 08, 2026

Apr 07, 2026

Will Annovis Bio Inc benefit from government policyEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Options Flow: Can Annovis Bio Inc deliver consistent dividendsChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Apr 06, 2026

Apr 06, 2026

Growth Value: Whats the analyst consensus on Annovis Bio IncMarket Movers & Verified Chart Pattern Signals - baoquankhu1.vn

Apr 06, 2026

Apr 06, 2026

Annovis Strengthens Patent Portfolio With Buntanetap, Stock Up - RTTNews

Apr 06, 2026

Apr 06, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Apr 06, 2026

Apr 04, 2026

ANVS.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat

Apr 03, 2026

Apr 03, 2026

Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView — Track All Markets

Apr 03, 2026

Apr 03, 2026

Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan

Apr 03, 2026

Apr 02, 2026

Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia

Apr 02, 2026

Apr 02, 2026

[144] Annovis Bio, Inc. SEC Filing - Stock Titan

Apr 02, 2026

Apr 02, 2026

Annovis Bio, Inc. Secures Patent for Buntanetap in Prevention and Treatment of Neurological Injuries from Infectious Agents - Quiver Quantitative

Apr 02, 2026